Viking Therapeutics, Inc. (VKTX)

Market Cap	3.93B
Revenue (ttm)	n/a
Net Income (ttm)	-237.39M
Shares Out	112.45M
EPS (ttm)	-2.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,770,947
Open	35.77
Previous Close	35.93
Day's Range	34.61 - 36.04
52-Week Range	18.92 - 81.73
Beta	0.64
Analysts	Strong Buy
Price Target	85.54 (+144.89%)
Earnings Date	Oct 22, 2025

About VKTX

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 29, 2015
• Employees: 36
• Stock Exchange: NASDAQ
• Ticker Symbol: VKTX
• Website: https://www.vikingtherapeutics.com

Analyst Summary

According to 13 analysts, the average rating for VKTX stock is "Strong Buy." The 12-month stock price target is $85.54, which is an increase of 144.89% from the latest price.

Price Target

$85.54

(144.89% upside)

Analyst Consensus: Strong Buy